United Kingdom Immunotherapy Market By Technology Type (Monoclonal Antibodies, Cytokines & Immunomodulators, Inhibitors, Others), By Indication Type (Oncology, Autoimmune Disease, Infectious Diseases, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Research & Academic Institutions, Others), By Region, Competition Forecast & Opportunities, 2018-2028F

The United Kingdom Immunotherapy Market is anticipated to grow at a significant rate in the projected period, 2024-2028. Immunotherapy has revolutionized the field of healthcare by harnessing the power of the immune system to fight diseases such as cancer, autoimmune disorders, and infectious diseases. In the United Kingdom, the immunotherapy market has experienced significant growth in recent years, with innovative therapies providing new hope for patients and healthcare providers alike. The United Kingdom boasts a robust ecosystem of pharmaceutical companies, research institutions, and healthcare providers actively engaged in the development and adoption of immunotherapy.

Immunotherapy makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. Numerous forms of cancer can be treated using immunotherapy. It may be used alone or in conjunction with other cancer treatments such as chemotherapy. When other therapies fail, immunotherapy may be effective. Immunotherapy can help some tumors, such as skin cancer, that do not react well to chemotherapy or radiation, start to disappear, leading to the growth of the United Kingdom Immunotherapy Market. Compared to other therapies, it has fewer negative effects. This is due to the fact that only the immune system is affected, not all of the body's cells.

The UK has witnessed remarkable advancements in various immunotherapy approaches. One notable breakthrough is the development of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which have shown exceptional efficacy in treating various types of cancer. These therapies work by targeting specific molecules that inhibit the immune system's response, thereby reactivating the body's natural defenses against cancer cells. Another significant advancement is the advent of CAR-T cell therapy, a form of adoptive cell transfer. This groundbreaking approach involves modifying a patient's T cells to express chimeric antigen receptors (CARs) that can recognize and eliminate cancer cells. CAR-T therapies, such as Kymriah and Yescarta, have demonstrated remarkable success in treating certain types of leukemia and lymphoma, which is expected to grow the United Kingdom Immunotherapy Market in the forecast period.

According to the International Agency for Research on Cancer, 457,960 new cancer cases and 179,648 cancer deaths were reported in the United Kingdom in 2020

Growing Adoption of Liquid Biopsy Propels United Kingdom's Immunotherapy Market

Immunotherapy has revolutionized cancer treatment, offering new hope to patients by harnessing the body's immune system to fight cancer cells. In recent years, the United Kingdom has witnessed a significant shift in cancer diagnostics and treatment, with liquid biopsy emerging as a preferred alternative to traditional tissue biopsy. This non-invasive technique has gained traction and is driving the growth of the country's immunotherapy market.

Liquid biopsy enhances the ability to identify patients who are most likely to benefit from immunotherapy. By profiling circulating tumor DNA, clinicians can predict response rates and select patients who have specific genetic alterations or biomarkers associated with a favorable immunotherapy response. This personalized approach leads to improved patient outcomes and cost-effective utilization of immunotherapies, propelling the growth of the United Kingdom Immunotherapy Market.

Liquid biopsy facilitates patient enrollment in clinical trials by identifying individuals with specific genetic alterations or biomarkers relevant to the trial's target population. This streamlined process accelerates the development of novel immunotherapies and enables access to cutting-edge treatments for patients. Liquid biopsy also enables regular monitoring of treatment response and disease progression. This monitoring allows for timely modifications to immunotherapy regimens, ensuring optimal treatment outcomes.

Additionally, liquid biopsy can aid in detecting minimal residual disease, allowing for earlier intervention and potentially preventing relapse, which is expected to propel the growth of the United Kingdom Immunotherapy Market. Furthermore, the ability to perform repeated liquid biopsies during the course of treatment provides real-time insights into the effectiveness of therapy. By monitoring circulating tumor DNA or RNA, clinicians can identify emerging resistance mechanisms, enabling timely adjustments to treatment plans and personalized care, hence propelling the growth of the United Kingdom's Immunotherapy Market in the forecast period.

Expanding usage of Target Therapy Propels the United Kingdom Immunotherapy Market

According to the Office for National Statistics, in 2021, the total current healthcare expenditure increased by 7.1% in real terms, compared to 10.0% in 2020, after accounting for the effects of inflation on the economy

One of the key factors contributing to the rising adoption of targeted therapy in the United Kingdom is the remarkable advancements in genomic research and technology. The availability of advanced genetic testing methods has enabled healthcare professionals to identify specific genetic alterations or biomarkers in patients, helping them select the most suitable targeted therapies and leading to the expansion of the United Kingdom Immunotherapy Market. This precise approach ensures that patients receive treatments that are more likely to be effective and minimizes unnecessary side effects.

Another crucial driver for the increased adoption of targeted therapy is the growing availability and accessibility of these treatments in the United Kingdom. Pharmaceutical companies are heavily investing in research and development to bring new targeted therapies to the market. Regulatory bodies have also streamlined the approval process, allowing faster access to these innovative treatments. Moreover, advancements in manufacturing and distribution processes have made targeted therapies more accessible to patients across the country.

The benefits of targeted therapy are not limited to improved treatment outcomes and accessibility. This approach also contributes to cost savings in the long run. By precisely targeting the disease-causing mechanisms, targeted therapies can reduce the need for extensive and costly treatments, such as chemotherapy or radiation therapy, which often have significant side effects. Additionally, targeted therapy can potentially shorten the treatment duration, resulting in lower healthcare costs and a more efficient allocation of resources.

The increasing adoption of targeted therapy in the United Kingdom Immunotherapy Market has not only transformed the treatment landscape but has also stimulated research and development in the field. Pharmaceutical companies and academic institutions are investing in further understanding the underlying mechanisms of diseases and developing new targeted therapies to address unmet medical needs, leading to the growth of the United Kingdom Immunotherapy Market.

Recent Developments

• In May 2023, the immunotherapy medication pembrolizumab (Keytruda) became accessible to people with certain types of advanced cervical cancer in England and Scotland. According to preliminary trial findings, pembrolizumab can, on average, delay the progression of some terminal cervical cancers for 8 months longer than existing therapies and might enable some cervical cancer patients to live longer overall. It is the first immunotherapy to be approved in the UK for the treatment of cervical cancer.
• In February 2023, Dxcover raised USD12.40 million to develop a pioneering liquid biopsy platform for early-stage cancers.

Mergers and Acquisitions

• In November 2021, a collaboration between the Royal Marsden NHS Foundation Trust and Guardant Health, a leading precision oncology company, resulted in the establishment of a cutting-edge liquid biopsy testing center for cancer clinical diagnosis and research. The Royal Marsden has also utilized liquid biopsies in clinical trials and has developed its own testing capabilities. On the other hand, the partnership with Guardant Health will ensure that researchers have access to more powerful tools based on massive datasets and sophisticated analytics, helping to identify more cancer patients for clinical trials with targeted treatments.

Market Segmentation

United Kingdom Immunotherapy Market is segmented into Technology Type, Indication Type,

Company Profiles

Johnson & Johnson, Novartis AG, Bayer AG, AstraZeneca, Pfizer Inc., Sanofi, GlaxoSmithKline plc, Amgen, Inc, AbbVie, Inc, F. Hoffmann-La Roche Ltd are some of the key players of United Kingdom Immunotherapy market.